ClinicalTrials.gg
CompletedNCT03706079DESTINATIONUpdated Jun 6, 2023Results posted

Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma

A Phase 3 interventional study of Tezepelumab and Placebo in Asthma, sponsored by AstraZeneca. Completed at 180 sites in 18 countries. Open to participants aged 13 Years to 81 Years. Per ClinicalTrials.gov, last updated 2023-06-06.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
951
Allocation
Randomized
Ages
13 Years to 81 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies testing tezepelumab in Asthma — 7 open to participants now, 8 under way, 5 of them phase 3. tezepelumab · Asthma.

Enrollment
2nd of 28
951 · median 121
Started
2019
with 4 others
Phase 3
16 of 28
4 open now
Registered
8th of 28
by date
Lead sponsor
16 of 28
AstraZeneca

Among the 28 studies testing tezepelumab in Asthma, this one is the 2nd largest by enrollment, is one of 5 that started in 2019, is one of 16 in phase 3, and was the 8th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 28 studies testing tezepelumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tezepelumab

tezepelumab: first FDA approval 2021 (TEZSPIRE), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 13 Years to 81 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing tezepelumab in Asthma, or all of them as a file.
02

Study summary

Subjects who completed either D5180C00007 or D5180C00009 will be offered the opportunity to consent for the Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma. The study consists of a treatment phase, followed by a follow-up phase where subjects will not receive IP. The length of the follow up phase is determined by which study the subject had previously completed.

Read the detailed description

Subjects who have not met investigational product discontinuation criteria and have attended the EOT visit in either study D5180C00007 or D5180C00009 will be offered the opportunity to consent for the Multicentre, Double-blind, Randomized, Parallel Group, Placebo Controlled, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab versus placebo in Adults and Adolescents (12 years of age and older) with a history of asthma exacerbations and inadequately controlled severe asthma receiving medium or high dose inhaled corticosteroid (ICS) plus at least one additional asthma controller medication with or without oral corticosteroids

Following treatment, subjects will enter a follow-up phase, determined by the predecessor study they had previously completed. Subjects will not receive IP during the follow-up phase. For subjects who entered the study from study D5180C00007 and did not meet IP Discontinuation criteria, the follow-up phase will extend from week 104 to Week 140. Subjects who entered the study from study D5180C00009 will have their follow-up phase extend to week 116.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma, Uncontrolled Asthma, Severe Uncontrolled Asthma
04

Who can participate

Ages eligible
13 Years to 81 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated written
  • Negative urine test for female subjects of prior to administration of IP at visit 1
  • Females of childbearing potential who are sexually active with a nonsterilized male partner must use a highly effective method of from screening, and must agree to continue using such precautions for 16 weeks after the final dose of IP.
  • Female or male subjects who have not met product discontinuation criteria and have attended the EOT visit in either study D5180C00007 (NAVIGATOR) or D5180C00009 (SOURCE)

To enter the extended follow-up phase of the study, the following inclusion criteria also apply:

  • Provision of signed and dated Addendum for Extended Follow-up to informed consent, as well as assent by adolescent subjects where applicable, prior to any mandatory study specific procedures, sampling and analyses before Extended Follow Up.
  • Must have entered DESTINATION from D5180C00007 study and have completed IP dosing to Week 100, have not met IP Discontinuation criteria and have attended the EOT Visit.

Exclusion criteria

Exclusion Criteria:

  • Any pulmonary disease other than asthma
  • Any disorder, including, but not limited to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major physical impairment that is not stable
  • History of chronic alcohol or drug abuse within 12 months prior to visit 1
  • Current or malignancy that developed during a predecessor study
  • Major surgery or planned surgical procedures requiring general anesthesia or inpatient status for > 1 day during the conduct of the study
  • Treatment with systemic /immunomodulating drugs except for OCS used in the treatment of asthma/asthma exacerbations within the last 12 weeks prior to randomization
  • Concurrent enrolment in another clinical study involving an IP
  • Any clinically meaningful abnormal finding in physical examination, vital signs, ,haematology, clinical chemistry, or urinalysis during the predecessor study
  • Pregnant, breastfeeding, or lactating

To enter the extended follow-up phase of the study (which extends from week 104 to week 140), the following exclusion criteria also apply:

  • Discontinuation of IP during the treatment period of DESTINATION.
  • Entered DESTINATION from D5180C00009 (SOURCE) study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
951 participants (actual)

Study arms

  • Experimental
    Tezepelumab

    Tezepelumab subcutaneous injection

    Biological: Tezepelumab

  • Placebo comparator
    Placebo

    Placebo: Placebo subcutaneous injection

    Other: Placebo

Interventions

  • BiologicalTezepelumab

    Tezepelumab subcutaneous injection

  • OtherPlacebo

    Placebo subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Exposure Adjusted Incidence Rates of AEs/SAEs

    Includes adverse events with an onset date between the date of first dose of IP in the predecessor and minimum (date of last dose of IP + 33 days, date of death, date of study withdrawal, day prior to start of another biologic). The analysis is based on the Safety Analysis Set. Exposure adjusted rates are defined as number of subjects with AEs divided by total time at risk across all subjects, multiplied by 100

    Time frame: Baseline (Week 0 in predecessor study) to Week 104. For subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION, all data collected after first dose of tezepelumab are excluded.

  2. Total Time at Risk

    Includes time between the date of first dose of IP in the predecessor and minimum (date of last dose of IP + 33 days, date of death, date of study withdrawal, day prior to start of another biologic). The analysis is based on the Safety Analysis Set.

    Time frame: Baseline (Week 0 in predecessor study) to Week 104. For subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION, all data collected after first dose of tezepelumab are excluded.

Secondary outcomes

  1. Annualized Asthma Exacerbation Rate (AAER)

    The annualized exacerbation rate is based on exacerbations reported by the investigator in the eCRF. The analysis is based on the primary population (Full Analysis Set)

    Time frame: Baseline (Week 0 in predecessor study) to Week 104. For subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION, all data collected after first dose of tezepelumab are excluded.

07

Results

Posted Feb 9, 2023

Participant flow

Participants who completed treatment and attended end of treatment visit in predecessor studies NAVIGATOR (NCT03347279) or SOURCE (NCT03406078) were eligible for this long-term extension study. In the predecessor studies, a total of 1059 and 150 subjects were randomised and dosed in NAVIGATOR and SOURCE respectively. In DESTINATION, a total of 951 subjects (827 from NAVIGATOR and 124 from SOURCE) were randomised at 182 centres in 18 countries to receive treatment with tezepelumab or placebo.

Predecessor Study
Participant flow — Predecessor Study
MilestoneNAVIGATOR Rand TezeNAVIGATOR Rand PboNAVIGATOR Pbo to TezeSOURCE Rand TezeSOURCE Rand PboSOURCE Pbo to Teze
Started529532074760
Received treatment528531074760
Completed513509068730
Not completed16230630
Withdrew: Death020100
Withdrew: Lost to follow-up520010
Withdrew: Withdrawal by subject8150520
Withdrew: Did not receive treatment / non-compliance with protocol / did not complete safety follow-up visits340000
Long Term Extension (DESTINATION)
Participant flow — Long Term Extension (DESTINATION)
MilestoneNAVIGATOR Rand TezeNAVIGATOR Rand PboNAVIGATOR Pbo to TezeSOURCE Rand TezeSOURCE Rand PboSOURCE Pbo to Teze
Started415206206603232
Received treatment415206205603232
Completed400200198582831
Not completed1568241
Withdrew: Due to covid-19 pandemic000001
Withdrew: Did not complete safety follow-up visits102000
Withdrew: Pregnancy100000
Withdrew: Withdrawal by subject333130
Withdrew: Lost to follow-up211010
Withdrew: Death822100

Outcome measures

SecondaryAnnualized Asthma Exacerbation Rate (AAER)

The annualized exacerbation rate is based on exacerbations reported by the investigator in the eCRF. The analysis is based on the primary population (Full Analysis Set)

Time frame:
Baseline (Week 0 in predecessor study) to Week 104. For subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION, all data collected after first dose of tezepelumab are excluded.
Reported as:
Least squares mean · events per year
Annualized Asthma Exacerbation Rate (AAER)
events per yearNAVIGATOR Rand TezeNAVIGATOR Rand PboSOURCE Rand TezeSOURCE Rand Pbo
Annualized Asthma Exacerbation Rate (AAER)0.82 (0.71 to 0.95)1.93 (1.70 to 2.20)1.07 (0.76 to 1.51)1.76 (1.27 to 2.45)
Statistical analysis
  • NAVIGATOR Rand Teze vs NAVIGATOR Rand Pbo · Rate ratio: 0.42 · 95% CI 0.35 to 0.51
  • SOURCE Rand Teze vs SOURCE Rand Pbo · Rate ratio: 0.61 · 95% CI 0.38 to 0.96
PrimaryExposure Adjusted Incidence Rates of AEs/SAEs

Includes adverse events with an onset date between the date of first dose of IP in the predecessor and minimum (date of last dose of IP + 33 days, date of death, date of study withdrawal, day prior to start of another biologic). The analysis is based on the Safety Analysis Set. Exposure adjusted rates are defined as number of subjects with AEs divided by total time at risk across all subjects, multiplied by 100

Time frame:
Baseline (Week 0 in predecessor study) to Week 104. For subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION, all data collected after first dose of tezepelumab are excluded.
Reported as:
Number · Patients with AEs per 100 person-years
Exposure Adjusted Incidence Rates of AEs/SAEs
Patients with AEs per 100 person-yearsNAVIGATOR Rand TezeNAVIGATOR Rand PboSOURCE Rand TezeSOURCE Rand Pbo
Any AE incidence rate49.6262.6647.1569.97
Any AE with outcome=death incidence rate0.760.141.550.00
Any SAE incidence rate7.8512.4513.1417.99
Any AE leading to discontinuation of IP incidence rate1.643.001.552.00
PrimaryTotal Time at Risk

Includes time between the date of first dose of IP in the predecessor and minimum (date of last dose of IP + 33 days, date of death, date of study withdrawal, day prior to start of another biologic). The analysis is based on the Safety Analysis Set.

Time frame:
Baseline (Week 0 in predecessor study) to Week 104. For subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION, all data collected after first dose of tezepelumab are excluded.
Reported as:
Number · Year
Total Time at Risk
YearNAVIGATOR Rand TezeNAVIGATOR Rand PboSOURCE Rand TezeSOURCE Rand Pbo
Total Time at Risk917.0699.0129.4100.0

Adverse events

Collected over Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period). Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NAVIGATOR Rand Teze8/528 (1.5%)82/528 (15.5%)390/528 (73.9%)
NAVIGATOR Rand Pbo5/531 (0.9%)94/531 (17.7%)384/531 (72.3%)
NAVIGATOR Pbo to Teze1/206 (0.5%)17/206 (8.3%)98/206 (47.6%)
SOURCE Rand Teze2/74 (2.7%)18/74 (24.3%)53/74 (71.6%)
SOURCE Rand Pbo0/76 (0%)19/76 (25%)58/76 (76.3%)
SOURCE Pbo to Teze0/32 (0%)4/32 (12.5%)23/32 (71.9%)
Most frequent serious events
Showing 10 of 178
Most frequent serious events
EventNAVIGATOR Rand TezeNAVIGATOR Rand PboNAVIGATOR Pbo to TezeSOURCE Rand TezeSOURCE Rand PboSOURCE Pbo to Teze
AsthmaRespiratory, thoracic and mediastinal disorders14/52841/5315/2063/748/760/32
AsthmaRespiratory, thoracic and mediastinal disorders16/52843/5315/2065/748/760/32
Covid-19 pneumoniaInfections and infestations3/5282/5310/2063/740/760/32
EncephaloceleCongenital, familial and genetic disorders0/5280/5310/2060/740/761/32
Gastrointestinal haemorrhageGastrointestinal disorders0/5280/5310/2060/740/761/32
Pneumonia haemophilusInfections and infestations0/5280/5310/2060/740/761/32
Ovarian germ cell teratoma benignNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/5280/5310/2060/740/761/32
Intracranial aneurysmNervous system disorders0/5280/5310/2060/740/761/32
Lumbar radiculopathyNervous system disorders0/5280/5310/2060/740/761/32
Transient ischaemic attackNervous system disorders1/5281/5310/2060/740/761/32
Most frequent other events
Showing 10 of 72
Most frequent other events
EventNAVIGATOR Rand TezeNAVIGATOR Rand PboNAVIGATOR Pbo to TezeSOURCE Rand TezeSOURCE Rand PboSOURCE Pbo to Teze
NasopharyngitisInfections and infestations130/528124/53121/20618/7422/767/32
Upper respiratory tract infectionInfections and infestations72/52891/5316/20612/749/760/32
HeadacheNervous system disorders58/52854/53113/2069/7410/761/32
HypertensionVascular disorders30/52826/5314/2065/747/764/32
Covid-19Infections and infestations7/5288/53110/2065/741/764/32
BronchitisInfections and infestations29/52839/5312/2069/743/760/32
AsthmaRespiratory, thoracic and mediastinal disorders14/52825/5312/2066/749/760/32
Bronchitis bacterialInfections and infestations30/52819/5313/2068/747/763/32
SinusitisInfections and infestations30/52843/5315/2062/745/761/32
Oral candidiasisInfections and infestations12/52815/5312/2065/746/762/32

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)NAVIGATOR Rand TezeNAVIGATOR Rand PboSOURCE Rand TezeSOURCE Rand PboTotal
<=18 years41410082
Between 18 and 65 years3914165862927
>=65 years96741614200
Age, Continuous
Age, Continuous(Years)NAVIGATOR Rand TezeNAVIGATOR Rand PboSOURCE Rand TezeSOURCE Rand PboTotal
Mean49.9 ± 16.349.0 ± 15.953.5 ± 12.153.4 ± 11.949.9 ± 15.7
Sex: Female, Male
Sex: Female, Male(Participants)NAVIGATOR Rand TezeNAVIGATOR Rand PboSOURCE Rand TezeSOURCE Rand PboTotal
Female3353374945766
Male1931942531443
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)NAVIGATOR Rand TezeNAVIGATOR Rand PboSOURCE Rand TezeSOURCE Rand PboTotal
Hispanic or Latino83811014188
Not Hispanic or Latino44545064621021
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)NAVIGATOR Rand TezeNAVIGATOR Rand PboSOURCE Rand TezeSOURCE Rand PboTotal
American Indian or Alaska Native01001
Asian1461491111317
Black of African American30311062
Native Hawaiian or Other Pacific Islander10001
Other19230143
White3323276264785
08

Study locations

180 sites
  • Research Site
    Dothan, Alabama 36303, United States
  • Research Site
    Gilbert, Arizona 85234, United States
  • Research Site
    Bakersfield, California 93301, United States
  • Research Site
    Huntington Beach, California 92647, United States
  • Research Site
    Long Beach, California 90808, United States
  • Research Site
    Los Angeles, California 90025, United States
  • Research Site
    Newport Beach, California 92663, United States
  • Research Site
    Northridge, California 91324, United States
  • Research Site
    Palm Desert, California 92260, United States
  • Research Site
    Rolling Hills Estates, California 90274, United States
  • Research Site
    Walnut Creek, California 94598, United States
  • Research Site
    Westminster, California 92683, United States
  • Research Site
    New Haven, Connecticut 06519, United States
  • Research Site
    Kissimmee, Florida 34744, United States
  • Research Site
    Kissimmee, Florida 34746, United States
  • Research Site
    Port Charlotte, Florida 33952, United States
  • Research Site
    Sarasota, Florida 34239, United States
  • Research Site
    Tampa, Florida 33607, United States
  • Research Site
    Winter Park, Florida 32789-4681, United States
  • Research Site
    Boise, Idaho 83706, United States
  • Research Site
    Zachary, Louisiana 70791, United States
  • Research Site
    White Marsh, Maryland 21162, United States
  • Research Site
    Boston, Massachusetts 02115, United States
  • Research Site
    Ann Arbor, Michigan 48109, United States
  • Research Site
    Saint Louis, Missouri 63141, United States
  • Research Site
    Lincoln, Nebraska 68510, United States
  • Research Site
    Las Vegas, Nevada 89119, United States
  • Research Site
    Northfield, New Jersey 08225, United States
  • Research Site
    Bronx, New York 10459, United States
  • Research Site
    Bronx, New York 10461, United States
  • Research Site
    Brooklyn, New York 11235, United States
  • Research Site
    Charlotte, North Carolina 28207, United States
  • Research Site
    Durham, North Carolina 27705, United States
  • Research Site
    Winston-Salem, North Carolina 27104, United States
  • Research Site
    Cincinnati, Ohio 45229, United States
  • Research Site
    Cincinnati, Ohio 45236, United States
  • Research Site
    Edmond, Oklahoma 73034, United States
  • Research Site
    Oklahoma City, Oklahoma 73120, United States
  • Research Site
    Medford, Oregon 97504, United States
  • Research Site
    Philadelphia, Pennsylvania 19140, United States
  • Research Site
    Anderson, South Carolina 29621, United States
  • Research Site
    Columbia, South Carolina 29204, United States
  • Research Site
    Greenville, South Carolina 29607, United States
  • Research Site
    Amarillo, Texas 79109, United States
  • Research Site
    Boerne, Texas 78006, United States
  • Research Site
    McKinney, Texas 75069, United States
  • Research Site
    McKinney, Texas 75071, United States
  • Research Site
    Plano, Texas 75093, United States
  • Research Site
    San Antonio, Texas 78251, United States
  • Research Site
    Manassas, Virginia 20110, United States
  • Research Site
    Cudahy, Wisconsin 53110, United States
  • Research Site
    Madison, Wisconsin 53792, United States
  • Research Site
    Buenos Aires, 1027, Argentina
  • Research Site
    Buenos Aires, C1414AIF, Argentina
  • Research Site
    Caba, C1425BEN, Argentina
  • Research Site
    Ciudad de Buenos Aires, 1425, Argentina
  • Research Site
    Córdoba, X5003DCE, Argentina
  • Research Site
    Mendoza, 5500, Argentina
  • Research Site
    Nueve de julio, B6500EZL, Argentina
  • Research Site
    Quilmes, B1878FNR, Argentina
  • Research Site
    San Fernando, B1646EBJ, Argentina
  • Research Site
    San Miguel de Tucuman, T4000IAQ, Argentina
  • Research Site
    Kent Town, 5067, Australia
  • Research Site
    Melbourne, 3004, Australia
  • Research Site
    New Lambton, 2310, Australia
  • Research Site
    Spearwood, 6163, Australia
  • Research Site
    Westmead, 2145, Australia
  • Research Site
    Woolloongabba, 4102, Australia
  • Research Site
    Wien, 1090, Austria
  • Research Site
    Wien, 1130, Austria
  • Research Site
    Blumenau, 89030-101, Brazil
  • Research Site
    Botucatu, 18618-970, Brazil
  • Research Site
    Curitiba, 80060-900, Brazil
  • Research Site
    Porto Alegre, 9002-060, Brazil
  • Research Site
    Porto Alegre, 90020-090, Brazil
  • Research Site
    Porto Alegre, 90610-000, Brazil
  • Research Site
    Porto Alegre, 91350-200, Brazil
  • Research Site
    Recife, 50070-550, Brazil
  • Research Site
    Salvador, 40060-330, Brazil
  • Research Site
    Santo Andre, 09080-110, Brazil
  • Research Site
    Sao Bernardo do Campo, 09750-420, Brazil
  • Research Site
    Sorocaba, 18040-425, Brazil
  • Research Site
    Calgary, Alberta T2N 4Z6, Canada
  • Research Site
    Sherwood Park, Alberta T8L 0N2, Canada
  • Research Site
    Ajax, Ontario L1S 2J5, Canada
  • Research Site
    Mississauga, Ontario L5A 3V4, Canada
  • Research Site
    Ottawa, Ontario K1H 1E4, Canada
  • Research Site
    Windsor, Ontario N8X 1T3, Canada
  • Research Site
    Montreal, Quebec H4J 1C5, Canada
  • Research Site
    St Charles Borromee, Quebec J6E 2B4, Canada
  • Research Site
    Trois-Rivières, Quebec G8T 7A1, Canada
  • Research Site
    Quebec, G1G 3Y8, Canada
  • Research Site
    Brest Cedex 2, 29609, France
  • Research Site
    Le Kremlin-Bicêtre, 94270, France
  • Research Site
    Lyon Cedex 04, 69317, France
  • Research Site
    Marseille Cedex 20, 13915, France
  • Research Site
    Montpellier, 34090, France
  • Research Site
    Nantes, 44093, France
  • Research Site
    Paris, 75012, France
  • Research Site
    Paris, 75018, France

Showing the first 100 of 180 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Menzies-Gow A, Ponnarambil S, Downie J, Bowen K, Hellqvist A, Colice G. DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma. Respir Res. 2020 Oct 21;21(1):279. doi: 10.1186/s12931-020-01541-7. PubMed 33087119 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Oct 2021, 33 months.

Results were first posted in Feb 2023, 1 year 3 months after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 33 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2018
First posted
Oct 15, 2018
StartActual
Jan 7, 2019
Primary completionActual
Oct 26, 2021
CompletionActual
May 18, 2022
Results first posted
Feb 9, 2023
Last update
Jun 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03706079
Lead sponsor
AstraZeneca
Collaborators
Amgen
Responsible party
Sponsor
First posted
Oct 15, 2018
Start date
Jan 7, 2019
Primary completion
Oct 26, 2021
Completion
May 18, 2022
Results posted
Feb 9, 2023
Last update
Jun 6, 2023

Study contacts

Andrew Menzies-Gow, MD
principal investigator · Royal Brompton Hospital, United Kingdom

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tezepelumab

Start the discussion